Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018)
Language English Country Netherlands Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
31901449
DOI
10.1016/j.clinph.2019.11.002
PII: S1388-2457(19)31279-9
Knihovny.cz E-resources
- Keywords
- Cortex, Indication, Neurology, Neuromodulation, Noninvasive brain stimulation, Psychiatry, Treatment,
- MeSH
- Mental Disorders therapy MeSH
- Humans MeSH
- Evidence-Based Medicine standards MeSH
- Nervous System Diseases therapy MeSH
- Practice Guidelines as Topic * MeSH
- Transcranial Magnetic Stimulation adverse effects methods standards MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
A group of European experts reappraised the guidelines on the therapeutic efficacy of repetitive transcranial magnetic stimulation (rTMS) previously published in 2014 [Lefaucheur et al., Clin Neurophysiol 2014;125:2150-206]. These updated recommendations take into account all rTMS publications, including data prior to 2014, as well as currently reviewed literature until the end of 2018. Level A evidence (definite efficacy) was reached for: high-frequency (HF) rTMS of the primary motor cortex (M1) contralateral to the painful side for neuropathic pain; HF-rTMS of the left dorsolateral prefrontal cortex (DLPFC) using a figure-of-8 or a H1-coil for depression; low-frequency (LF) rTMS of contralesional M1 for hand motor recovery in the post-acute stage of stroke. Level B evidence (probable efficacy) was reached for: HF-rTMS of the left M1 or DLPFC for improving quality of life or pain, respectively, in fibromyalgia; HF-rTMS of bilateral M1 regions or the left DLPFC for improving motor impairment or depression, respectively, in Parkinson's disease; HF-rTMS of ipsilesional M1 for promoting motor recovery at the post-acute stage of stroke; intermittent theta burst stimulation targeted to the leg motor cortex for lower limb spasticity in multiple sclerosis; HF-rTMS of the right DLPFC in posttraumatic stress disorder; LF-rTMS of the right inferior frontal gyrus in chronic post-stroke non-fluent aphasia; LF-rTMS of the right DLPFC in depression; and bihemispheric stimulation of the DLPFC combining right-sided LF-rTMS (or continuous theta burst stimulation) and left-sided HF-rTMS (or intermittent theta burst stimulation) in depression. Level A/B evidence is not reached concerning efficacy of rTMS in any other condition. The current recommendations are based on the differences reached in therapeutic efficacy of real vs. sham rTMS protocols, replicated in a sufficient number of independent studies. This does not mean that the benefit produced by rTMS inevitably reaches a level of clinical relevance.
Department of Clinical Neurophysiology University Medical Center Göttingen Göttingen Germany
Department of Psychiatry and Psychotherapy University Hospital LMU Munich Munich Germany
Department of Psychiatry and Psychotherapy University of Regensburg Regensburg Germany
Department of Psychiatry Princess Grace Hospital Monaco
ENT Clinic Mehiläinen and University of Turku Turku Finland
FENNSI Group Hospital Nacional de Parapléjicos SESCAM Toledo Spain
References provided by Crossref.org
Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review
Is the vertex a good control stimulation site? Theta burst stimulation in healthy controls
